Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sildenafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 20/20 | 0.92 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.92 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.92 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.92 |
| ▸ | PDE2A | O00408 | 1/20 | 0.92 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.92 |
| ▸ | PDE6D | O43924 | 1/20 | 0.92 |
| ▸ | PDE8A | O60658 | 1/20 | 0.92 |
| ▸ | PDE9A | O76083 | 1/20 | 0.92 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.92 |
| ▸ | HTR1A | P08908 | 1/20 | 0.92 |
| ▸ | PDE6A | P16499 | 1/20 | 0.92 |
| ▸ | PDE6G | P18545 | 1/20 | 0.92 |
| ▸ | PDE4A | P27815 | 1/20 | 0.92 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.92 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.92 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.92 |
| ▸ | PDE6B | P35913 | 1/20 | 0.92 |
| ▸ | PDE6C | P51160 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sildenafil SCHEMBL29144808 | 0.98 | PDE5A (0.94) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL17200208 | 0.97 | PDE5A (0.92) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL1895 | 0.96 | PDE5A (1.00) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL29361663 | 0.96 | PDE5A (1.00) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL5683880 | 0.96 | PDE5A (1.00) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL5804786 | 0.95 | PDE5A (0.90) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL3399278 | 0.95 | PDE5A (0.95) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL7915871 | 0.95 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL1801562 | 0.95 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL19410952 | 0.95 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006069806-A1 | PHARMACEUTICAL COMPOSITION COMPRINSING A 2,5-DIHYDROXYBENZENESULFONIC COMPOUNDS, A POTASSIUM ION CHANNEL MODULATOR AND A PHOSPHODIESTERASE TYPE 5 INHIBITOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-06 | — | — | WO | claimed |
| EP-1676573-A1 | Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-05 | — | — | EP | claimed |
| EP-1652521-A1 | Pharmaceutical composition of sildenafil and a large conductance Ca(2+) activated K+ channels activator | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-05-03 | — | — | EP | claimed |
| WO-2015161510-A1 | SAA DERIVATIVE COMPOUND RESTORES ENOS AND INHIBITS OXIDATIVE STRESS-INDUCED DISEASES IN HYPOXIA | JANSFAT BIOTECHNOLOGY CO., LTD. (CN) | 2015-10-29 | — | — | WO | disclosed |
| US-20150306107-A1 | SAA Derivative Compound Restores eNOS And Inhibits Oxidative Stress-Induced A Diseases In Hypoxia | JANSFAT BIOTECHNOLOGY CO., LTD. (TW) | 2015-10-29 | — | — | US | disclosed |
| EP-2152276-A1 | SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS | Traffick Therapeutics Inc. (CA) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008138123-A1 | SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS | THOMAS DAVID Y (CA) | 2008-11-20 | — | — | WO | disclosed |
| US-20080095718-A1 | METHODS AND COMPOSITIONS FOR TREATING ERECTILE DYSFUNCTION | ARADIGM CORPORATION | 2008-04-24 | — | — | US | disclosed |
| US-20080008661-A1 | METHODS AND COMPOSITIONS FOR TREATING ERECTILE DYSFUNCTION | ARADIGM CORPORATION | 2008-01-10 | — | — | US | disclosed |
| US-7258850-B2 | Methods and compositions for treating erectile dysfunction | ARADIGM CORPORATION (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1677754-A1 | METHODS AND COMPOSITIONS FOR TREATING ERECTILE DYSFUNCTION | ARADIGM CORPORATION (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006069806-A1 | PHARMACEUTICAL COMPOSITION COMPRINSING A 2,5-DIHYDROXYBENZENESULFONIC COMPOUNDS, A POTASSIUM ION CHANNEL MODULATOR AND A PHOSPHODIESTERASE TYPE 5 INHIBITOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-06 | — | — | WO | disclosed |
| EP-1676573-A1 | Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-05 | — | — | EP | disclosed |
| EP-1652521-A1 | Pharmaceutical composition of sildenafil and a large conductance Ca(2+) activated K+ channels activator | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035905-A1 | Formulations of phosphodiesterase 5 inhibitors and methods of use | BECTON, DICKINSON AND COMPANY (US) | 2006-02-16 | — | — | US | disclosed |
| WO-2005077374-A1 | FORMULATIONS OF PHOSPHODIESTERASE 5 INHIBITORS AND METHODS OF USE | BECTON, DICKINSON AND COMPANY (US) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005039530-A1 | METHODS AND COMPOSITIONS FOR TREATING ERECTILE DYSFUNCTION | ARADIGM CORPORATION (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20040208829-A1 | Methods and compositions for treating erectile dysfunction | ARADIGM CORPORATION | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306107-A1 | SAA Derivative Compound Restores eNOS And Inhibits Oxidative Stress-Induced A Diseases In Hypoxia | SAAL1, HMOX1, HIF1AN | PDE5A 342/4885PDE3B 157/4885PDE3A 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.